Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04126200
Title Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline

multiple myeloma


belantamab mafodotin-blmf + Isatuximab

belantamab mafodotin-blmf + Dostarlimab-gxly

belantamab mafodotin-blmf + GSK3359609

belantamab mafodotin-blmf + Nirogacestat

belantamab mafodotin-blmf

belantamab mafodotin-blmf + GSK3174998

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN

No variant requirements are available.